ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 497

Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis

Ilana Golub1, Jennifer Wang2, Ani Shahbazian1, John Moriarty1 and Christina Charles-Schoeman3, 1University of California, Los Angeles, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA, 3Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, lipids and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with rheumatoid arthritis (RA) have a marked increase in cardiovascular (CV) morbidity and mortality compared to the general population. Conventional lipid profiles are insufficient to stratify CV risk in this population, and may not capture many of the lipoprotein abnormalities which predispose to atherosclerosis (ATH). Nuclear magnetic resonance (NMR) spectroscopy simultaneously quantifies the number, size, and composition of lipoprotein particles, providing a better understanding of the modifications in each lipoprotein. The current work investigated the relationship of lipoprotein profiles by NMR spectroscopy with progression of carotid ATH in a longitudinal cohort of patients with RA.

Methods: The study population included 119 RA patients who had carotid ultrasounds performed at 2 time points separated by a mean ± SD of 5.5 ± 1.2 years at a single academic center. The number and type of carotid plaques were assessed, and an ATH score provided by the same radiologist for all scans. Fasting blood was collected for lipoprotein analysis, inflammatory markers, and lipoprotein particle profiles measured by NMR spectroscopy (Liposcience Inc. Raleigh, North Carolina, USA). Traditional cardiovascular risk factors, medication use, and RA disease characteristics were assessed for all patients at baseline and follow-up visits.

Results:

In RA patients without baseline carotid ATH, mean large very low density lipoprotein (VLDL) particle concentrations were significantly higher in patients with incident plaque formation over the follow-up period, compared to patients without incident plaque formation (p<0.05). Similar trends were noted in evaluation of all RA patients with plaque progression regardless of baseline ATH status. In multivariate analysis controlling for significant traditional CV risk factors, RA disease characteristics, medication use, and the presence of carotid plaque on baseline ultrasound, large VLDL concentrations remained significantly associated with increased risk of carotid plaque progression measured by ≥ one unit increase in carotid ATH score (p<0.05). Similar results were noted when defining ATH progression by ≥ one new carotid plaque from the baseline scan. Triglyceride levels were also significantly associated with plaque progression in univariate analysis, but did not remain significant in multivariate analysis. Mean total, LDL, and HDL cholesterol levels were not associated with carotid ATH progression in this cohort.

Conclusion:

The current work suggests a relationship between large VLDL particles and cardiovascular risk in RA patients as assessed by the progression of carotid ATH over 5 year longitudinal follow-up. Further CV outcome studies may be warranted to determine if large VLDL particles are a useful biomarker of CV risk in patients with RA.


Disclosure: I. Golub, None; J. Wang, None; A. Shahbazian, None; J. Moriarty, None; C. Charles-Schoeman, Bristol Myers Squibb, AbbVie, Octapharma, and Pfizer, 2,Regeneron-Sanofi, Pfizer, Octapharma, Amgen, and Gilead, 5.

To cite this abstract in AMA style:

Golub I, Wang J, Shahbazian A, Moriarty J, Charles-Schoeman C. Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/increased-concentration-of-large-very-low-density-lipoprotein-particles-associates-with-progression-of-carotid-atherosclerosis-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-concentration-of-large-very-low-density-lipoprotein-particles-associates-with-progression-of-carotid-atherosclerosis-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology